Clinical Psychopharmacology Institute Faculty

Wilson M. Compton, M.D., M.P.E. is Deputy Director of the National Institute on Drug Abuse of the National Institutes of Health. Before joining NIDA in 2002, Dr. Compton was a tenured faculty member in the Department of Psychiatry and Director of the Master in Psychiatric Epidemiology Program at Washington University in Saint Louis as well as Medical Director of Addiction Services at the Barnes-Jewish Hospital. Dr. Compton received his undergraduate education from Amherst College. He attended medical school and completed residency training in psychiatry at Washington University in Saint Louis.

Over his career, Dr. Compton has achieved multiple scientific accomplishments. He has authored over 200 publications, including widely-cited papers on the U.S. opioid crisis., and has been an invited speaker at multiple high-impact venues. He was a member of DSM-5’s Revision Task Force and has led, for NIDA, development of the Population Assessment of Tobacco and Health Study (PATH), a longitudinal population study, jointly sponsored by NIDA and the U.S. Food and Drug Administration (FDA), with 45,971 baseline participants who provide survey responses and biological assessments to inform the development of tobacco regulations in the United States.

Dr. Compton is a member of numerous professional organizations, including the Alpha Omega Alpha medical education honor society. Dr. Compton is also the recipient of multiple awards, including the Senior Scholar Health Services Research Award from the American Psychiatric Association in 2008 and the Paul Hoch Award from the American Psychopathological Association in 2010. The FDA selected him to receive collaboration and cross-cutting awards in 2012, 2013 and 2017. In 2018, Dr. Compton received the James W. West award from the National Association of Addiction Treatment Providers. Dr. Compton also received the Health and Human Services Secretary’s Awards for Meritorious Service in 2013 and Distinguished Service in 2015, 2018 2019, and most recently in 2024, for his work on the CMS-NIH-CDC-SAMHSA Opioid Policy Data Team.

KEYNOTE SPEAKER

Jonathan M. Meyer, M.D.
Voluntary Clinical Professor of Psychiatry – University of California, San Diego; Distinguished Life Fellow, American Psychiatric Association

Dr. Jonathan Meyer is a Voluntary Clinical Professor of Psychiatry at University of California, San Diego, and a Distinguished Life Fellow of the American Psychiatric Association. Dr. Meyer is a graduate of Stanford University and Harvard Medical School, finished his adult psychiatry residency at LA County-USC Medical Center and completed fellowships there in Consultation/Liaison Psychiatry and Psychopharmacology Research. Dr. Meyer has teaching duties at UC San Diego and the Balboa Naval Medical Center, and is a psychopharmacology consultant to the first episode psychosis program at Balboa NMC

Dr. Meyer has lectured and published extensively on psychopharmacology, and is the sole author of the chapter on the Pharmacotherapy of Psychosis and Mania for the last 3 editions of Goodman & Gilman’s The Pharmacological Basis of Therapeutics. Along with Dr. Stephen Stahl he is co-author of the Clozapine Handbook published in 2019, The Clinical Use of Antipsychotic Plasma Levels released in 2021, and The Lithium Handbook published in 2023, all three by Cambridge University Press.